- Home
- NWG vs BDX Comparison
NWG vs BDX Comparison
Compare NWG & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWG | BDX |
|---|---|---|
| Founded | 1727 | 1897 |
| Country | United Kingdom | United States |
| Employees | 58700 | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.6B | 51.5B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | NWG | BDX |
|---|---|---|
| Price | $15.01 | $143.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $186.00 |
| AVG Volume (30 Days) | ★ 3.7M | 3.0M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.57% | 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $14.83 | N/A |
| Revenue Next Year | $7.43 | $3.02 |
| P/E Ratio | ★ $18.92 | $577.32 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $12.91 | $142.83 |
| 52 Week High | $19.36 | $213.08 |
Technical Indicators
Market Signals| Indicator | NWG | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 38.94 |
| Support Level | $14.63 | N/A |
| Resistance Level | $15.80 | $158.66 |
| Average True Range (ATR) | 0.26 | 4.35 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 21.05 | 7.96 |
Price Performance
Historical ComparisonAbout NWG NatWest Group plc (each representing two (2))
NatWest Group derives around 90% of its total income from the United Kingdom. The bank operates a retail, commercial, and private bank in the UK, offering clients lending and payment services as well as asset management services.
About BDX Becton Dickinson and Company
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.